These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 23314138)

  • 1. Mild hypomagnesemia as the most common Cisplatin nephropathy in Iran.
    Mashhadi MA; Heidari Z; Zakeri Z
    Iran J Kidney Dis; 2013 Jan; 7(1):23-7. PubMed ID: 23314138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The Incidence of Cisplatin-induced Hypomagnesemia in Cervical Cancer Patients Receiving Cisplatin Alone].
    Yamamoto Y; Watanabe K; Matsushita H; Tsukiyama I; Matsuura K; Wakatsuki A
    Yakugaku Zasshi; 2017; 137(1):79-82. PubMed ID: 28049899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer.
    Thongprasert S; Chewaskulyong B
    J Med Assoc Thai; 2004 Oct; 87(10):1162-7. PubMed ID: 15560691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective evaluation of furosemide and mannitol for prevention of cisplatin-induced nephrotoxicity.
    Mach CM; Kha C; Nguyen D; Shumway J; Meaders KM; Ludwig M; Williams-Brown MY; Anderson ML
    J Clin Pharm Ther; 2017 Jun; 42(3):286-291. PubMed ID: 28276070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of Factors Influencing the Development of Hypomagnesemia in Patients Receiving Cetuximab Therapy for Head and Neck Cancer].
    Inose R; Takahashi K; Nishikawa T; Nagayama K
    Yakugaku Zasshi; 2015; 135(12):1403-7. PubMed ID: 26632157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.
    Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
    Eur J Cancer; 2009 Dec; 45(18):3213-9. PubMed ID: 19850470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
    Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
    Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: a report on patient compliance and acute toxicity.
    Serkies K; Jassem J
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):814-21. PubMed ID: 15465198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin and hypomagnesemia.
    Lajer H; Daugaard G
    Cancer Treat Rev; 1999 Feb; 25(1):47-58. PubMed ID: 10212589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effect of intra-peritoneal epinephrine on postoperative renal function after cisplatin-based intra-peritoneal intra-operative chemotherapy.
    Pili-Floury S; Royer B; Bartholin F; Crumiere N; Combe M; Chalopin JM; Pivot X; Heyd B; Chauffert B; Samain E
    Eur J Obstet Gynecol Reprod Biol; 2011 Jun; 156(2):199-203. PubMed ID: 21306815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity of hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric patients with sarcomatosis/carcinomatosis: early experience and phase 1 results.
    Hayes-Jordan A; Green H; Ludwig J; Anderson P
    Pediatr Blood Cancer; 2012 Aug; 59(2):395-7. PubMed ID: 22492588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal impairment and hypertension in brain tumor patients treated in childhood are mainly associated with cisplatin treatment.
    Pietilä S; Ala-Houhala M; Lenko HL; Harmoinen AP; Turjanmaa V; Mäkipernaa A
    Pediatr Blood Cancer; 2005 Apr; 44(4):363-9. PubMed ID: 15586356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anesthetic management and renal function in pediatric patients undergoing cytoreductive surgery with continuous hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin.
    Owusu-Agyemang P; Arunkumar R; Green H; Hurst D; Landoski K; Hayes-Jordan A
    Ann Surg Oncol; 2012 Aug; 19(8):2652-6. PubMed ID: 22451231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
    Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
    J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose cisplatin as neoadjuvant organ-preserving chemotherapy for squamous cell carcinoma of the larynx.
    Lacava JA; Ferreyra R; Leone BA; Losada C; Elem YL; Vallejo CT
    Cancer J Sci Am; 1996; 2(1):46-51. PubMed ID: 9166498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic evaluation of cisplatin, etoposide, and bleomycin chemotherapy regimen in high-risk gestational trophoblastic neoplasia].
    Song SQ; Zhang GN
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):571-6. PubMed ID: 23141175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
    Biró K
    Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.